A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Cedars-Sinai led clinical trial that showed treatment reduced deaths in patients with an aggressive form of the disease.